Karen E Hoffman1, Jiangong Niu2, Yu Shen3, Jing Jiang3, John W Davis4, Jeri Kim5, Deborah A Kuban1, George H Perkins1, Jay B Shah3, Grace L Smith1, Robert J Volk6, Thomas A Buchholz1, Sharon H Giordano2, Benjamin D Smith1. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston. 2. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston. 4. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston. 5. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 6. Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston.
Abstract
IMPORTANCE: Up-front treatment of older men with low-risk prostate cancer can cause morbidity without clear survival benefit; however, most such patients receive treatment instead of observation. The impact of physicians on the management approach is uncertain. OBJECTIVE: To determine the impact of physicians on the management of low-risk prostate cancer with up-front treatment vs observation. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort of men 66 years and older with low-risk prostate cancer diagnosed from 2006 through 2009. Patient and tumor characteristics were obtained from the Surveillance, Epidemiology, and End Results cancer registries. The diagnosing urologist, consulting radiation oncologist, cancer-directed therapy, and comorbid medical conditions were determined from linked Medicare claims. Physician characteristics were obtained from the American Medical Association Physician Masterfile. Mixed-effects models were used to evaluate management variation and factors associated with observation. MAIN OUTCOMES AND MEASURES: No cancer-directed therapy within 12 months of diagnosis (observation). RESULTS: A total of 2145 urologists diagnosed low-risk prostate cancer in 12,068 men, of whom 80.1% received treatment and 19.9% were observed. The case-adjusted rate of observation varied widely across urologists, ranging from 4.5% to 64.2% of patients. The diagnosing urologist accounted for 16.1% of the variation in up-front treatment vs observation, whereas patient and tumor characteristics accounted for 7.9% of this variation. After adjustment for patient and tumor characteristics, urologists who treat non-low-risk prostate cancer (adjusted odds ratio [aOR], 0.71 [95% CI, 0.55-0.92]; P = .01) and graduated in earlier decades (P = .004) were less likely to manage low-risk disease with observation. Treated patients were more likely to undergo prostatectomy (aOR, 1.71 [95% CI, 1.45-2.01]; P < .001), cryotherapy (aOR, 28.2 [95% CI, 19.5-40.9]; P < .001), brachytherapy (aOR, 3.41 [95% CI, 2.96-3.93]; P < .001), or external-beam radiotherapy (aOR, 1.31 [95% CI, 1.08-1.58]; P = .005) if their urologist billed for that treatment. Case-adjusted rates of observation also varied across consulting radiation oncologists, ranging from 2.2% to 46.8% of patients. CONCLUSIONS AND RELEVANCE: Rates of management of low-risk prostate cancer with observation varied widely across urologists and radiation oncologists. Patients whose diagnosis was made by urologists who treated prostate cancer were more likely to receive up-front treatment and, when treated, more likely to receive a treatment that their urologist performed. Public reporting of physicians' cancer management profiles would enable informed selection of physicians to diagnose and manage prostate cancer.
IMPORTANCE: Up-front treatment of older men with low-risk prostate cancer can cause morbidity without clear survival benefit; however, most such patients receive treatment instead of observation. The impact of physicians on the management approach is uncertain. OBJECTIVE: To determine the impact of physicians on the management of low-risk prostate cancer with up-front treatment vs observation. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort of men 66 years and older with low-risk prostate cancer diagnosed from 2006 through 2009. Patient and tumor characteristics were obtained from the Surveillance, Epidemiology, and End Results cancer registries. The diagnosing urologist, consulting radiation oncologist, cancer-directed therapy, and comorbid medical conditions were determined from linked Medicare claims. Physician characteristics were obtained from the American Medical Association Physician Masterfile. Mixed-effects models were used to evaluate management variation and factors associated with observation. MAIN OUTCOMES AND MEASURES: No cancer-directed therapy within 12 months of diagnosis (observation). RESULTS: A total of 2145 urologists diagnosed low-risk prostate cancer in 12,068 men, of whom 80.1% received treatment and 19.9% were observed. The case-adjusted rate of observation varied widely across urologists, ranging from 4.5% to 64.2% of patients. The diagnosing urologist accounted for 16.1% of the variation in up-front treatment vs observation, whereas patient and tumor characteristics accounted for 7.9% of this variation. After adjustment for patient and tumor characteristics, urologists who treat non-low-risk prostate cancer (adjusted odds ratio [aOR], 0.71 [95% CI, 0.55-0.92]; P = .01) and graduated in earlier decades (P = .004) were less likely to manage low-risk disease with observation. Treated patients were more likely to undergo prostatectomy (aOR, 1.71 [95% CI, 1.45-2.01]; P < .001), cryotherapy (aOR, 28.2 [95% CI, 19.5-40.9]; P < .001), brachytherapy (aOR, 3.41 [95% CI, 2.96-3.93]; P < .001), or external-beam radiotherapy (aOR, 1.31 [95% CI, 1.08-1.58]; P = .005) if their urologist billed for that treatment. Case-adjusted rates of observation also varied across consulting radiation oncologists, ranging from 2.2% to 46.8% of patients. CONCLUSIONS AND RELEVANCE: Rates of management of low-risk prostate cancer with observation varied widely across urologists and radiation oncologists. Patients whose diagnosis was made by urologists who treated prostate cancer were more likely to receive up-front treatment and, when treated, more likely to receive a treatment that their urologist performed. Public reporting of physicians' cancer management profiles would enable informed selection of physicians to diagnose and manage prostate cancer.
Authors: Claire F Snyder; Kevin D Frick; Amanda L Blackford; Robert J Herbert; Bridget A Neville; Michael A Carducci; Craig C Earle Journal: Cancer Date: 2010-08-23 Impact factor: 6.860
Authors: Scott D Ramsey; Steven B Zeliadt; Catherine R Fedorenko; David K Blough; Carol M Moinpour; Ingrid J Hall; Judith Lee Smith; Donatus U Ekwueme; Megan E Fairweather; Ian M Thompson; Thomas E Keane; David F Penson Journal: World J Urol Date: 2010-10-20 Impact factor: 4.226
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Patrick O Richard; Shabbir M H Alibhai; Tony Panzarella; Laurence Klotz; Maria Komisarenko; Neil E Fleshner; David Urbach; Antonio Finelli Journal: Can Urol Assoc J Date: 2016 Sep-Oct Impact factor: 1.862
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677